Singapore markets close in 4 hours 35 minutes

Adial Pharmaceuticals, Inc. (ADIL)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.7000-0.2000 (-10.53%)
At close: 04:00PM EDT
1.6900 -0.01 (-0.59%)
After hours: 07:23PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.9000
Open1.8600
Bid1.6500 x 100
Ask1.7400 x 100
Day's range1.6600 - 1.8744
52-week range0.7700 - 14.0000
Volume439,727
Avg. volume6,513,622
Market cap6.893M
Beta (5Y monthly)1.53
PE ratio (TTM)N/A
EPS (TTM)-4.9100
Earnings date10 May 2024 - 14 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est17.00
  • Benzinga

    EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent

    On April 16, 2024, the United States Patent and Trademark Office issued patent number 11957664 to Adial Pharmaceuticals Inc (NASDAQ:ADIL). This patent expands Adial’s intellectual property protection and covers the combination of the company’s proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder (AUD) and other drug dependencies, such as opioid use disorder (OUD), with the company’s lead investigational new drug pr

  • GlobeNewswire

    Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

    GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office. This patent expands Adial’s intellectual property protection and covers the combination of the Company’s proprietary g

  • GlobeNewswire

    Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

    Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinical trialGLEN ALLEN, Va., April 10, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the publication of a peer-reviewed article highlighting the promising clinical results, strong safety profile and high c